Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 2/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27055137 | 0.83 | CYP17A1 (0.37) | RXFP1TNKSDAOLMNAMAPT | |
| SCHEMBL10149394 | 0.79 | DAO (0.39) | RXFP1DAO | |
| SCHEMBL1884167 | 0.71 | DAO (0.58) | TNKSDAO | |
| SCHEMBL27054264 | 0.71 | ADORA2A (0.43) | — | |
| SCHEMBL15468282 | 0.71 | KIF11 (0.44) | DAOLMNAMAPT | |
| SCHEMBL25823816 | 0.70 | TLR7 (0.46) | LMNA | |
| SCHEMBL18670873 | 0.69 | CYP3A4 (0.33) | TNKSDAOLMNAMAPT | |
| SCHEMBL15946957 | 0.67 | BRD4 (0.44) | BRAFDAO | |
| SCHEMBL22210762 | 0.65 | BRAF (0.40) | BRAFMAPT | |
| SCHEMBL25823819 | 0.64 | KDM4E (0.42) | RXFP1BRAFMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648086-B2 | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors | ASCEPION PHARMACEUTICALS, INC. (CN) | 2014-02-11 | — | — | US | disclosed |
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | RXFP1 4443/4885TNKS 767/4885BRAF 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.